MarketHLP005
Company Profile

HLP005

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.

Pharmacology
Pharmacodynamics HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic. In addition, HLP005 may also inhibit serotonin and dopamine reuptake. ==Chemistry==
Chemistry
(CYB2108; CYB210010). In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature. Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions). ==Research==
Research
HLP005 is under development by Helus Pharma (formerly Cybin). ==See also==
tickerdossier.comtickerdossier.substack.com